Dosing & Uses
Dosage Forms & Strengths
topical liquid
- 0.5%
- 1%
- 2%
- 3%
- 6%
- 12.6%
- 13.6%
- 16.7%
- 17%
- 17.6%
- 26%
- 27.5%
gel
- 2%
- 6%
- 17%
lotion
- 3%
- 6%
cream
- 2%
- 6%
aerosol/foam
- 6%
soap
- 2%
- 3%
strips
- 40%
pad
- 40%
disk
- 40%
plaster
- 40%
patch
- 15%
- 40%
Plantar Warts/Calluses/Corn
Hydrate skin prior to application by soaking in warm water for 5 min, then use a cloth, brush, or emery board to loosened wart tissue; dry skin thoroughly
Liquid (27.5%): Protect surrounding unaffected skin with petrolatum, then apply liquid to each wart and allow to dry before applying a second application; repeat two application process once or twice daily for up to 6 weeks
Liquid (17%) or gel: Apply to clean dry area at each wart and allow to dry; apply qDay or q12hr up to 12 weeks
Gel (6%): Apply to affected area qDay; may apply at night and rinse off in the morning
Foam: Apply to affected area q12hr; rub into skin until completely absorbed
Patch (15%): Apply directly over affected area qHS and remove in the morning for up to 12 weeks; patch should be trimmed to cover affected area
Patch (40%): Apply directly over affected area and leave in place for 48hr; may repeat for up to 12 weeks; may trim patch to cover affected area or secure with adhesive strips
Plasters/strips: Apply as directed per individual product
Product content varies, check individual labeling
Seborrheic Dermatitis/Psoriasis
Ointment (3%): Apply to plaques or scales on skin up to q6hr (not for use on scalp or face)
Cream (2.5%): Apply to affected area q6-8hr; may be left in place overnight depending on the product
Shampoo (1.8-3%): Massage product into wet hair or affected area and leave in place for several minutes; rinse thoroughly; may apply two or three times/week or as directed by a healthcare professional; may be left in place overnight depending on the product
Foam: Apply to affected area q12hr; rub into skin until completely absorbed
Keratolytic for treating skin/scalp seborrhea or psoriasis
Dosage Forms & Strengths
topical liquid
- 0.5%
- 1%
- 2%
- 3%
- 6%
- 12.6%
- 13.6%
- 16.7%
- 17%
- 17.6%
- 26%
- 27.5%
gel
- 2%
- 6%
- 17%
lotion
- 3%
- 6%
cream
- 2%
- 6%
aerosol/foam
- 6%
soap
- 2%
- 3%
strips
- 40%
pad
- 40%
disk
- 40%
plaster
- 40%
patch
- 15%
- 40%
Plantar Warts/Calluses/Corn
<12 years
- Safety & efficacy not established
>12 years
- Hydrate skin prior to application by soaking in warm water for 5 min, then use a cloth, brush, or emery board to loosened wart tissue; dry skin thoroughly
- Liquid (27.5%): Protect surrounding unaffected skin with petrolatum, then apply liquid to each wart and allow to dry before applying a second application; repeat two application process once or twice daily for up to 6 weeks
- Liquid (17%) or gel: Apply to clean dry area at each wart and allow to dry; apply qDay or q12hr up to 12 weeks
- Gel (6%): Apply to affected area qDay; may apply at night and rinse off in the morning
- Foam: Apply to affected area q12hr; rub into skin until completely absorbed
- Patch (15%): Apply directly over affected area qHS and remove in the morning for up to 12 weeks; patch should be trimmed to cover affected area
- Patch (40%): Apply directly over affected area and leave in place for 48hr; may repeat for up to 12 weeks; may trim patch to cover affected area or secure with adhesive strips
- Plasters/strips: Apply as directed per individual product Product content varies, check individual labeling
Adverse Effects
Frequency Not Defined
Stinging/burning of skin
Dizziness
Headache
Tinnitus
Mental confusion
Peeling
Scaling
Burning/irritaion on normal tissue at site of exposure
Hyperventilation
Warnings
Contraindications
Hypersensitivity
Prolonged use or application to large areas (risk for salicylism)
Children < 2 years
Virasal
- Impaired circulaiton (diabetes)
- Warts with hair growth or on face
- Birthmarks
- Moles
Cautions
External topical use only
Avoid contact with eyes
Caution in infants, diabetics, or those with impaired circulation (diabetes)
Prolonged use over large areas, especially in children and those patients with significant renal or hepatic impairment, could result in salicylism
Avoid concomitant use of other drugs which may contribute to elevated serum salicylate levels when the potential for toxicity is present
In children <12 years and patients with renal or hepatic impairment, area to be treated should be limited and patient monitored closely for signs of salicylate toxicity, including nausea, vomiting, dizziness, loss of hearing, tinnitus, lethargy, hyperpnea, diarrhea, and psychic disturbances
In event of salicylic acid toxicity, discontinue use of SA 6%
Fluids should be administered to promote urinary excretion; treatment with sodium bicarbonate (oral or intravenous) should be instituted as appropriate
Patients should be cautioned against use of oral aspirin and other salicylate containing medications, such as sports injury creams, to avoid additional excessive exposure to salicylic acid
Where needed, aspirin should be replaced by alternative non-steroidal anti-inflammatory agent that is not salicylate based
Patients should be advised not to apply occlusive dressings, clothing or other occlusive topical products such as petrolatum-based ointments to prevent excessive systemic exposure to salicylic acid
Excessive application of product other than what is needed to cover affected area will not result in a more rapid therapeutic benefit
Due to potential risk of developing Reye's syndrome, salicylate products should not be used in children and teenagers with varicella or influenza, unless directed by physician
Pregnancy & Lactation
Pregnancy
Drug shown to be teratogenic in rats and monkeys; difficult to extrapolate from oral doses of acetylsalicylic acid used in these studies to topical administration as the oral dose to monkeys may represent six times the maximal daily human dose of salicylic acid when applied topically over a large body surface; there are no adequate and well-controlled studies in pregnant women.
Use SA 6% during pregnancy only if potential benefit justifies potential risk to fetus
Lactation
Because of potential for serious adverse reactions in nursing infants from mother's use of SA 6%, a decision should be made whether to discontinue nursing or discontinue drug, taking into account importance of drug to mother; if used by nursing mothers, should not be used on chest area to avoid accidental contamination of child
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Dissolves the intracellular cement that causes the hyperkeratotic tissue to swell, macerate, soften, and desquamate
Product is keratolytic at 3-6% and destructive at concentrations >6%; concentrations of 6-60% are used to remove corns and warts in the treatment of psoriasis and other keratotic disorders
Pharmacokinetics
Absorption: None with normal percutaneous use
Peak plasma time: Within 5 hours with occlusion is used
Images
BRAND | FORM. | UNIT PRICE | PILL IMAGE |
---|---|---|---|
Compound W topical - | 17 % liquid | ![]() | |
Keralyt topical - | 6 % shampoo | ![]() | |
Keralyt topical - | 3 % gel | ![]() | |
UltraSal-ER topical - | 28.5 % solution | ![]() | |
DHS Sal topical - | 3 % shampoo | ![]() | |
salicylic acid topical - | 28.5 % solution | ![]() | |
salicylic acid topical - | 6 % lotion | ![]() | |
salicylic acid topical - | 6 % cream | ![]() | |
salicylic acid topical - | 6 % foam | ![]() | |
salicylic acid topical - | 6 % lotion | ![]() | |
salicylic acid topical - | 6 % shampoo | ![]() | |
salicylic acid topical - | 27.5 % liquid | ![]() | |
salicylic acid topical - | 6 % gel | ![]() | |
Neutrogena T/Sal topical - | 3 % shampoo | ![]() | |
Neutrogena Oil-Free Acne Wash topical - | 2 % liquid | ![]() | |
Virasal topical - | 27.5 % liquid | ![]() | |
MG217 Psoriasis (salicylic acid) topical - | 3 % cream | ![]() | |
Mediplast Corn-Callus-Wart Remover topical - | 40 % transdermal system | ![]() | |
Keralyt Scalp Complete topical - | 6-6 % shampoo | ![]() | |
Duofilm topical - | 17 % liquid | ![]() | |
Wart Remover topical - | 17 % liquid | ![]() | |
Wart Remover topical - | 17 % gel | ![]() | |
Wart Remover topical - | 17 % liquid | ![]() | |
Keralyt Rx topical - | 6 % gel | ![]() | |
Keralyt Rx topical - | 6 % gel | ![]() | |
Salvax topical - | 6 % foam | ![]() | |
Salvax topical - | 6 % foam | ![]() | |
Dr Scholl's Clear Away topical - | 40 % transdermal system | ![]() |
Copyright © 2010 First DataBank, Inc.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.